Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61M-025/10
A61F-002/82
A61F-002/02
출원번호
US-0123951
(2008-05-20)
등록번호
US-8414526
(2013-04-09)
발명자
/ 주소
Wang, Lixiao
출원인 / 주소
Lutonix, Inc.
대리인 / 주소
Dinsmore & Shohl, LLP
인용정보
피인용 횟수 :
30인용 특허 :
220
초록▼
The invention relates to a coated medical device for rapid delivery of a therapeutic agent to a tissue in seconds to minutes. The medical device has a layer overlying the exterior surface of the medical device. The layer contains a therapeutic agent, at least one of an oil, a fatty acid, and a lipid
The invention relates to a coated medical device for rapid delivery of a therapeutic agent to a tissue in seconds to minutes. The medical device has a layer overlying the exterior surface of the medical device. The layer contains a therapeutic agent, at least one of an oil, a fatty acid, and a lipid, and an additive. In certain embodiments, the additive has a hydrophilic part and a drug affinity part, wherein the drug affinity part is at least one of a hydrophobic part, a part that has an affinity to the therapeutic agent by hydrogen bonding, a part that has an affinity to the therapeutic agent by charge, and a part that has an affinity to the therapeutic agent by van der Waals interactions. In embodiments, the additive is at least one of a surfactant and a chemical compound. In further embodiments, the chemical compound is water-soluble.
대표청구항▼
1. A balloon catheter for the delivery of a therapeutic agent to a target site of a blood vessel, the balloon catheter comprising: a coating layer overlying an exterior surface of an inflatable balloon, the coating layer comprising: a hydrophobic therapeutic agent selected from the group consisting
1. A balloon catheter for the delivery of a therapeutic agent to a target site of a blood vessel, the balloon catheter comprising: a coating layer overlying an exterior surface of an inflatable balloon, the coating layer comprising: a hydrophobic therapeutic agent selected from the group consisting of paclitaxel, rapamycin, and combinations thereof;at least one water-soluble first additive selected from the group consisting of PEG sorbitan fatty esters, gluconolactone, lactobionic acid, and combinations thereof; andat least one water-insoluble second additive selected from the group consisting of phosphatidylcholine, phosphatidylethanolamine, dimyristoylphosphatidylcholine, and combinations thereof. 2. The balloon catheter of claim 1, wherein the at least one water-soluble first additive is selected from the group consisting of PEG sorbitan monolaurates, PEG sorbitan monooleates, gluconolactone, lactobionic acid, and combinations thereof. 3. The balloon catheter of claim 1, wherein the at least one water-soluble first additive is selected from the group consisting of PEG-20 sorbitan monolaurate, gluconolactone, lactobionic acid, and combinations thereof. 4. The balloon catheter of claim 1, wherein the at least one water-soluble first additive is selected from the group consisting of PEG-20 sorbitan monolaurate, gluconolactone, and combinations thereof. 5. The balloon catheter of claim 4, wherein the hydrophobic therapeutic agent is paclitaxel. 6. The balloon catheter of claim 1, wherein: the at least one water-soluble first additive is gluconolactone. 7. The balloon catheter of claim 6, wherein the hydrophobic therapeutic agent is paclitaxel. 8. The balloon catheter of claim 1, wherein: the at least one water-soluble first additive is lactobionic acid; andthe at least one water-insoluble second additive is phosphatidylcholine. 9. The balloon catheter of claim 8, wherein the hydrophobic therapeutic agent is paclitaxel. 10. The balloon catheter of claim 1, wherein: the at least one water-soluble first additive is PEG-20 sorbitan monolaurate; andthe at least one water-insoluble second additive is phosphatidylcholine. 11. The balloon catheter of claim 10, wherein the hydrophobic therapeutic agent is paclitaxel. 12. The balloon catheter of claim 1, wherein the balloon catheter includes one of a perfusion balloon catheter, an infusion catheter, a perforated balloon, a porous balloon, a weeping balloon, a cutting balloon catheter, or a scoring balloon catheter. 13. The balloon catheter of claim 1, further comprising an adherent layer between the exterior surface of the balloon catheter and the coating layer, the adherent layer comprising at least one additive selected from the group consisting of PEG sorbitan fatty esters, gluconolactone, lactobionic acid, phosphatidylcholine, phosphatidylethanolamine, dimyristoylphosphatidylcholine, and combinations thereof. 14. The balloon catheter of claim 1, further comprising a dimethylsulfoxide solvent layer overlying the surface of the coating layer. 15. The balloon catheter of claim 1, wherein the coating layer consists essentially of the hydrophobic therapeutic agent, the water-soluble first additive, and the water-insoluble second additive. 16. The balloon catheter of claim 1, wherein the coating layer further comprises sorbitol. 17. The balloon catheter of claim 1, wherein the concentration of the therapeutic agent in the coating layer is from 1 μg/mm2 to 20 μg/mm2. 18. The balloon catheter of claim 1, wherein the concentration of the therapeutic agent in the coating layer is from 2 μg/mm2 to 6 μg/mm2. 19. The balloon catheter of claim 1, wherein the total thickness of the coating layer is from 0.1 μm to 200 μm. 20. The balloon catheter of claim 1, wherein the hydrophobic therapeutic agent is not enclosed in micelles or liposomes and is not encapsulated in polymer particles. 21. The balloon catheter of claim 1, wherein the ratio by weight of the therapeutic agent in the coating layer to the total weight of the first and second additives in the coating layer is from about 0.5 to 3. 22. The balloon catheter of claim 1, further comprising a top layer overlying the surface of the coating layer, wherein the top layer comprises an additive that is less hydrophilic than the at least one water-soluble first additive in the coating layer, and wherein the additive in the top layer is selected from the group consisting of p-isononylphenoxypolyglycidol, PEG-20 sorbitan monolaurate, PEG-20 sorbitan monopalmitate, PEG-20 monostearate, PEG glyceryl laurate, PEG glyceryl oleate, PEG glyceryl stearate, polyglyceryl laurate, polyglyceryl oleate, polyglyceryl myristate, polyglyceryl palmitate, polyglyceryl-6 laurate, polyglyceryl-6 oleate, polyglyceryl-6 myristate, polyglyceryl-6 palmitate, polyglyceryl-10 laurate, polyglyceryl-10 oleate, polyglyceryl-10 myristate, polyglyceryl-10 palmitate, PEG sorbitan monolaurate, PEG sorbitan monolaurate, PEG sorbitan monooleate, PEG oleyl ether, PEG lauryl ether, octoxynol, monoxynol, tyloxapol, sucrose monopalmitate, sucrose monolaurate, decanoyl-N-methylglucamide, n-decyl-β-D-glucopyranoside, n-decyl-β-D-maltopyranoside, n-dodecyl-β-D-glucopyranoside, n-dodecyl-β-D-maltoside, heptanoyl-N-methylglucamide, n-heptyl-β-D-glucopyranoside, n-heptyl-β-D-thioglucoside, n-hexyl-β-D-glucopyranoside, nonanoyl-N-methylglucamide, n-nonyl-β-D-glucopyranoside, octanoyl-N-methylglucamide, n-octyl-β-D-glucopyranoside, octyl-β-D-thioglucopyranoside, cystine, tyrosine, tryptophan, leucine, isoleucine, phenylalanine, asparagine, aspartic acid, glutamic acid, methionine, ascorbic acid, 2-pyrrolidone-5-carboxylic acid, sodium pyrrolidone carboxylate, ethylenediaminetetraacetic dianhydride, cetotiamine; cyclothiamine, dexpanthenol, niacinamide, nicotinic acid, pyridoxal 5-phosphate, nicotinamide ascorbate, riboflavin, riboflavin phosphate, thiamine, folic acid, menadiol diphosphate, menadione sodium bisulfite, menadoxime, vitamin B12, vitamin K5, vitamin K6, vitamin U, albumin, benzalkonium chloride, benzethonium chloride, docecyl trimethyl ammonium bromide, sodium dodecylsulfates, dialkyl methylbenzyl ammonium chloride, dialkylesters of sodium sulfonsuccinic acid, L-ascorbic acid and its salts, D-glucoascorbic acid and its salts, tromethamine, triethanolamine, diethanolamine, meglumine, glucamine, amine alcohols, glucoheptonic acid, gluconic acid, hydroxy ketones, hydroxy lactones, gluconolactone, glucoheptonolactone, glucooctanoic lactone, gulonic acid lactone, mannoic lactone, ribonic acid lactone, lactobionic acid, glucosamine, glutamic acid, benzyl alcohol, benzoic acid, hydroxybenzoic acid, propyl 4-hydroxybenzoate, lysine acetate salt, gentisic acid, lactitol, sinapic acid, vanillic acid, vanillin, methyl paraben, propyl paraben, sorbitol, cyclodextrin, (2-hydroxypropyl)-cyclodextrin, acetaminophen, ibuprofen, retinoic acid, lysine acetate, gentisic acid, catechin, catechin gallate, tiletamine, ketamine, propofol, and combinations thereof. 23. The balloon catheter of claim 22, wherein the additive in the top layer is selected from the group consisting of PEG-20 sorbitan monolaurate, PEG-20 sorbitan monopalmitate, PEG-20 monostearate, PEG glyceryl laurate, PEG glyceryl oleate, PEG glyceryl stearate, polyglyceryl laurate, polyglyceryl oleate, polyglyceryl myristate, polyglyceryl palmitate, polyglyceryl-6 laurate, polyglyceryl-6 oleate, polyglyceryl-6 myristate, polyglyceryl-6 palmitate, polyglyceryl-10 laurate, polyglyceryl-10 oleate, polyglyceryl-10 myristate, and polyglyceryl-10 palmitate. 24. The balloon catheter of claim 23, wherein: the hydrophobic therapeutic agent is paclitaxel; andthe top layer further comprises paclitaxel. 25. A balloon catheter for the delivery of a therapeutic agent to a target site of a blood vessel, the balloon catheter comprising: a coating layer overlying an exterior surface of an inflatable balloon, the coating layer comprising: a hydrophobic therapeutic agent selected from the group consisting of paclitaxel, rapamycin, and combinations thereof;at least one water-soluble first additive selected from the group consisting of PEG sorbitan fatty esters, gluconolactone, lactobionic acid, and combinations thereof; andat least one water-insoluble second additive selected from the group consisting of soybean oil, vegetable oil, flower oil, coconut oil, palm oil, olive oil, fish oil, butanoic acid, hexanoic acid, octanoic acid, decanoic acid, dodecanoic acid, tetradecanoic acid, hexadecanoic acid, octadecanoic acid, octadecatrienoic acid, eicosanoic acid, eicosenoic acid, eicosatetraenoic acid, eicosapentaenoic acid, docosahexaenoic acid, tocotrienol, butyric acid, caproic acid, caprylic acid, capric acid, lauric acid, myristic acid, palmitic acid, palmitoleic acid, stearic acid, oleic acid, vaccenic acid, linoleic acid, alpha-linolenic acid, gamma-linolenic acid, behenic acid, erucic acid, lignoceric acid, and combinations thereof. 26. The balloon catheter of claim 25, wherein: the hydrophobic therapeutic agent is paclitaxel;the at least one water-soluble first additive is gluconolactone; andthe at least one water-insoluble second additive is selected from the group consisting of fish oil, soybean oil, and olive oil. 27. The balloon catheter of claim 25, wherein: the hydrophobic therapeutic agent is paclitaxel;the at least one water-soluble first additive is lactobionic acid; andthe at least one water-insoluble second additive is eicosapentaenoic acid. 28. The balloon catheter of claim 25, wherein: the hydrophobic therapeutic agent is paclitaxel;the at least one water-soluble first additive is PEG-20 sorbitan monolaurate; andthe at least one water-insoluble second additive is tocotrienol.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (220)
Caufield Craig E. (Princeton Junction NJ) Grinfeld Alexander A. (Princeton Junction NJ), 42-Epi-rapamycin and pharmaceutical compositions thereof.
Osbakken, Robert S.; Hale, Mary Anne; Leivo, Frederick T.; Munk, James D., Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis.
Daniel Castro ; Steven Wu ; Kevin L. Woolbright ; Kurt W. Scheinpflug ; Syed F. A. Hossainy ; Li Chen, Apparatus and method for depositing a coating onto a surface of a prosthesis.
Slepian Marvin J. (Cleveland Heights OH) Schindler Anton (Durham NC), Biodegradable polymeric endoluminal sealing process, apparatus and polymeric product for use therein.
Molnar-Kimber Katherine L. (Glenside PA) Ocain Timothy D. (Waltham MA) Vernon Steven K. (Havertown PA) Huang John J. (San Carlos CA), Biotin esters of rapamycin.
Solomon Donald D. (Spring Valley OH) Taller Robert A. (Centerville OH) Williamitis Victor A. (Dayton OH), Blood compatible, lubricious article and composition and method therefor.
Failli Amedeo A. (Princeton Junction NJ) Bleyman Oleg I. (Holland PA) Kao Wenling (Paoli PA) Abou-Gharbia Magid A. (Glen Mills PA), Carbamates of rapamycin.
Failli Amedeo A. (Princeton Junction NJ) Bleyman Oleg I. (Holland PA) Kao Wenling (Paoli PA) Abou-Gharbia Magid A. (Glen Mills PA), Carbamates of rapamycin.
Failli Amedeo A. (Princeton Junction NJ) Bleyman Oleg I. (Holland PA) Kao Wenling (Paoli PA) Abou-Gharbia Magid A. (Glen Mills PA), Carbamates of rapamycin.
Kao Wenling (Paoli PA) Skotnicki Jerauld S. (Allentown NJ) Abou-Gharbia Magid A. (Glen Mills PA) Palmer Yvette L. (Newtown PA), Carbamates of rapamycin.
Skotnicki Jerauld S. (Allentown NJ) Palmer Yvette L. (Newtown PA) Kao Wenling (Paoli PA) Abou-Gharbia Magid A. (Glen Mills PA), Carbamates of rapamycin.
Failli Amedeo A. (Princeton Junction NJ) Bleyman Oleg I. (Holland PA) Kao Wenling (Paoli PA) Abou-Gharbia Magid A. (Glen Mills PA), Carbamates of rapaycin.
Bacher Peter (Nurnberg DEX) Walenga Jeanine M. (Lombard IL), Catheter and method for the prevention and/or treatment of stenotic processes of vessels and cavities.
Fearnot Neal E. (West Lafayette IN) Kozma Thomas G. (West Lafayette IN) Ragheb Anthony O. (West Lafayette IN) Voorhees William D. (West Lafayette IN), Coated implantable medical device.
Ragheb, Anthony O.; Bates, Brian L.; Fearnot, Neal E.; Kozma, Thomas G.; Voorhees, III, William D.; Gershlick, Anthony H., Coated implantable medical device.
Amundson Rodney R. (Lindstrom MN) Hull Vincent W. (Ham Lake MN) Dror Michael (Edina MN) Schwartz Robert S. (Rochester MN), Drug delivery balloon catheter with line of weakness.
Fitzhugh,Anthony L.; Cafferata,Robert; Keefer,Larry K., Highly cross-linked, extremely hydrophobic nitric oxide-releasing polymers and methods for their manufacture and use.
Reiley Mark A. ; Scholten Arie ; Talmadge Karen D., Inflatable device for use in surgical protocols relating to treatment of fractured or diseased bones.
Armstrong Jay J. (Bensalem PA) Sehgal Surendra N. (Princeton NJ), Innovative technique for immunosuppression involving administration of rapamycin loaded formed blood elements.
Bucay-Couto, Weenna; Li, Jamie (Jianmin), Long-term indwelling medical devices containing slow-releasing antimicrobial agents and having a surfactant surface.
Skotnicki Jerauld S. (Allentown NJ) Failli Amedeo A. (Princeton Junction NJ) Steffan Robert J. (Langhorne NJ) Kearney Robert M. (Lawrenceville NJ), Macrocyclic immunomodulators.
Hostettler Fritz ; Rhum David ; Forman Michael R. ; Helmus Michael N. ; Ding Ni, Medical device coated with interpenetrating network of hydrogel polymers.
Rosen Gerald M. ; Herzog ; Jr. William R. ; Pou Sovitj, Medical device with a surface adapted for exposure to a blood stream which is coated with a polymer containing a nitrosy.
Fan You-Ling (East Brunswick NJ) Marlin Lawrence (Bridgewater NJ) Sahatjian Ronald A. (Lexington MA) Schultz Steven A. (Northboro MA), Medical device with lubricious coating.
Amundson Rodney R. (Lindstrom MN) Hull Vincent W. (Ham Lake MN) Dror Michael (Edina MN) Schwartz Robert S. (Rochester MN), Method for making a drug delivery balloon catheter.
Kinsella James L. (Baltimore MD) Sollott Steven J. (Baltimore MD), Method of treating atherosclerosis or restenosis using microtubule stabilizing agent.
Conway Anthony J. (Chatfield MN) Conway Philip J. (Chatfield MN) Fryar ; Jr. Richard D. (Rochester MN), Microcidal agent releasing catheter with balloon.
Roorda,Wouter E.; Ding,Ni; Pacetti,Stephen D.; Michal,Eugene T.; Shah,Ashok A.; Hossainy,Syed F. A., Polyacrylates coatings for implantable medical devices.
Failli Amedeo (Princeton Junction NJ) Kao Wenling (Paoli PA) Steffan Robert J. (Langhorne PA) Vogel Robert L. (Stratford NJ), Rapamycin 42-sulfonates and 42-(N-carbalkoxy) sulfamates useful as immunosuppressive agents.
Failli Amedeo A. (Princeton Junction NJ) Kao Wenling (Paoli PA) Steffan Robert J. (Langhorne PA) Vogel Robert L. (Stratford NJ), Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents.
Sehgal Surendra N. (Dollard des Ormeaux CA) Blazekovic Teodora M. (Mount Royal CA) Vezina Claude (Deux-Montagnes CA), Rapamycin and process of preparation.
Harrison Maureen M. (St. Albans VT) Ofslager Christian L. (Plattsburgh NY) Waranis Robert P. (Chazy NY) Leonard Thomas W. (Wilmington NC), Rapamycin formulations for oral administration.
Failli Amedeo A. (Princeton Junction NJ) Steffan Robert J. (Langhorne PA) Caufield Craig E. (Princeton Junction NJ) Hu David C. (Langhorne PA) Grinfeld Alexander A. (Princeton Junction NJ), Rapamycin oximes.
Failli Amedeo A. (Princeton Junction NJ) Steffan Robert J. (Langhorne PA) Caufield Craig E. (Princeton Junction NJ) Hu David C. (Langhorne PA) Grinfeld Alexander A. (Princeton Junction NJ), Rapamycin oximes.
Kao Wenling (Paoli PA) Vogel Robert L. (Stratford NJ) Abou-Gharbia Magid A. (Glen Mills PA) Caufield Craig E. (Princeton Junction NJ), Rapamycin oximes and hydrazones.
Roorda,Wouter E.; Hossainy,Syed F. A.; Ding,Ni; Tang,Fuh Wei; Pacetti,Stephen D., Rate limiting barriers for implantable devices and methods for fabrication thereof.
Gregory T. Sydney ; Russ Seiber ; Arthur R. Madenjian ; Annette Belovi, Selective coating of a balloon catheter with lubricious material for stent deployment.
Sydney Gregory T. ; Seiber Russ ; Madenjian Arthur R. ; Belovi Annette, Selective coating of a balloon catheter with lubricious material for stent deployment.
Ragheb Anthony O. ; Bates Brian L. ; Fearnot Neal E. ; Osborne Thomas A. ; Kozma Thomas G. ; Roberts Joseph W. ; Voorhees ; III William D., Silver implantable medical device.
Hostettler Fritz ; Rhum David ; Forman Michael R. ; Helmus Michael N. ; Ding Ni, Slippery, tenaciously adhering hydrogel coatings containing a polyurethane-urea polymer hydrogel commingled with a pol.
Kunz Lawrence L. ; Klein Richard A. ; Reno John M. ; Grainger David J.,GBX ; Metcalfe James C.,GBX ; Weissberg Peter L.,GBX ; Anderson Peter G., Therapeutic inhibitor of vascular smooth muscle cells.
Kunz Lawrence L. ; Klein Richard A. ; Reno John M. ; Grainger David J.,GBX ; Metcalfe James C.,GBX ; Weissberg Peter L.,GBX ; Anderson Peter G., Therapeutic inhibitor of vascular smooth muscle cells.
Fearnot Neal E. (West Lafayette IN) Ragheb Anthony O. (West Lafayette IN) Voorhees ; III William D. (West Lafayette IN), Thrombolytic treated intravascular medical device.
Baumbach, William R.; Sherman, Darren R.; Burgermeister, Robert, Balloon catheter systems for delivery of dry drug delivery vesicles to a vessel in the body.
Baumbach, William R.; Sherman, Darren R.; Burgermeister, Robert S., Balloon catheter systems for delivery of dry drug delivery vesicles to a vessel in the body.
Baumbach, William R.; Sherman, Darren R.; Burgermeister, Robert S., Balloon catheter systems for delivery of dry drug delivery vesicles to a vessel in the body.
Dugas, Tammy R.; Khandelwal, Alok; Kleinedler, James John; Foley, John Devlin, Coated devices and method of making coated devices that reduce smooth muscle cell proliferation and platelet activity.
Wang, Jeffrey; Malinoff, Harrison; Wang, Lixiao; Barry, Christopher M.; Wahr, Dennis W.; Naisbitt, Scott R., Methods and apparatuses for coating balloon catheters.
Wang, Jeffrey; Malinoff, Harrison; Wang, Lixiao; Barry, Christopher M.; Wahr, Dennis W.; Naisbitt, Scott R., Methods and apparatuses for coating balloon catheters.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.